182 related articles for article (PubMed ID: 22354778)
1. Comparative analysis of the Vitek 2 antifungal susceptibility system and E-test with the CLSI M27-A3 broth microdilution method for susceptibility testing of Indian clinical isolates of Cryptococcus neoformans.
Tewari A; Behera B; Mathur P; Xess I
Mycopathologia; 2012 Jun; 173(5-6):427-33. PubMed ID: 22354778
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of Sensititre YeastOne and VITEK 2 against the Clinical and Laboratory Standards Institute M27-E4 reference broth microdilution method for the antifungal susceptibility testing of Cryptococcus neoformans and Cryptococcus gattii.
Zhang M; Zhou Z; Wang D; Zhou A; Song G; Chen X; Guo J; Wu W
Med Mycol; 2022 Mar; 60(3):. PubMed ID: 35099022
[TBL] [Abstract][Full Text] [Related]
3. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the VITEK 2 system to test the susceptibility of Candida spp., Trichosporon asahii and Cryptococcus neoformans to amphotericin B, flucytosine, fluconazole and voriconazole: a comparison with the M27-A3 reference method.
Cejudo MA; Gallego AG; Lacasa EC; Aller AI; Romero A; García JP; Andrés GQ; Martín-Mazuelos E
Med Mycol; 2010 Aug; 48(5):710-9. PubMed ID: 20109092
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.
Mahabeer Y; Chang CC; Naidu D; Dorasamy A; Lewin S; Ndung'u T; Moosa MY; French M; Mlisana K; Coovadia Y
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):294-8. PubMed ID: 25277745
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study.
Borghi E; Iatta R; Sciota R; Biassoni C; Cuna T; Montagna MT; Morace G
J Clin Microbiol; 2010 Sep; 48(9):3153-7. PubMed ID: 20631105
[TBL] [Abstract][Full Text] [Related]
7. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya.
Mdodo R; Moser SA; Jaoko W; Baddley J; Pappas P; Kempf MC; Aban I; Odera S; Jolly P
Mycoses; 2011 Sep; 54(5):e438-42. PubMed ID: 21535451
[TBL] [Abstract][Full Text] [Related]
8. Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for
Delma FZ; Al-Hatmi AMS; Buil JB; van der Lee H; Tehupeiory-Kooreman M; de Hoog GS; Meletiadis J; Verweij PE
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015025
[TBL] [Abstract][Full Text] [Related]
9. Multicenter evaluation of the new Vitek 2 yeast susceptibility test using new CLSI clinical breakpoints for fluconazole.
Pfaller MA; Diekema DJ; Procop GW; Wiederhold NP
J Clin Microbiol; 2014 Jun; 52(6):2126-30. PubMed ID: 24719450
[TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
[TBL] [Abstract][Full Text] [Related]
11. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
[TBL] [Abstract][Full Text] [Related]
12. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of PASCO and national committee for clinical laboratory standards M27-A broth microdilution methods for antifungal drug susceptibility testing of yeasts.
Arthington-Skaggs BA; Motley M; Warnock DW; Morrison CJ
J Clin Microbiol; 2000 Jun; 38(6):2254-60. PubMed ID: 10834985
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
Morales BP; Trilles L; Bertho ÁL; Junior IN; de Oliveira Rde V; Wanke B; Lazéra Mdos S
Mycoses; 2015 May; 58(5):273-9. PubMed ID: 25756839
[TBL] [Abstract][Full Text] [Related]
15. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.
Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
J Clin Microbiol; 2007 Nov; 45(11):3522-8. PubMed ID: 17913927
[TBL] [Abstract][Full Text] [Related]
16. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method.
López-Jodra O; Torres-Rodríguez JM; Méndez-Vásquez R; Ribas-Forcadell E; Morera-López Y; Baró-Tomás T; Alia-Aponte C
J Antimicrob Chemother; 2000 May; 45(5):645-9. PubMed ID: 10797087
[TBL] [Abstract][Full Text] [Related]
18. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Etest and Neo-Sensitabs diffusion assays on Mueller-Hinton-methylene blue agar with broth microdilution reference method (CLSI-M27-A2) for testing susceptibilities of Cryptococcus neoformans to amphotericin B and fluconazole.
Ochiuzzi ME; Santiso GM; Arechavala AI
Med Mycol; 2010 Sep; 48(6):893-6. PubMed ID: 20370370
[TBL] [Abstract][Full Text] [Related]
20. Influence of capsule size on the in vitro activity of antifungal agents against clinical Cryptococcus neoformans var. grubii strains.
Vitale RG; Pascuccelli V; Afeltra J
J Med Microbiol; 2012 Mar; 61(Pt 3):384-388. PubMed ID: 22074850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
